Cycle view
- Bloc
- Organization
- Theory
- Practical
- Others
- Credits
| Code | Details | Bloc | Organization | Theory | Practical | Others | Credits |
|---|---|---|---|---|---|---|---|
| PHAR0344-3 | Medicines analysis | B1 | Q1 | 45 | 28 | - | 7 |
| PHAR0343-3 | Pharmaceutical technologies and biopharmacy (part I) | B1 | Q1 | 20 | 60 | - | 4 |
| PHAC0341-2 | Special pharmacology (Part I) | B1 | Q1 | 25 | - | - | 3 |
| TOXI0341-2 | Toxiocological chemistry, Part I | B1 | Q1 | 4 | |||
| Toxiocological chemistry | 25 | - | - | ||||
| Toxicological chemistry, supplement for pharmacy - [12h Seminar] | - | - | [+] | ||||
| BIOC0340-1 | Clinical Chemistry (Part I) - [12h Seminar] | B1 | Q1 | 22 | - | [+] | 4 |
| MBIO0002-1 | Pharmaceutical Microbiology | B1 | Q1 | 16 | - | - | 2 |
| PHAR2018-1 | Officinal pharmaceutical good practices - [6h Seminar] | B1 | Q1 | 10 | - | [+] | 2 |
| ECON0340-1 | Pharmacoeconomy | B1 | Q1 | 10 | - | - | 1 |
| PHAR0003-1
| Pharmaceutical tehcnologies and biopharmacy (part II) - [5h Seminar]
Corequisite
| B1 | Q2 | 25 | - | [+] | 4 |
| PHAR0347-3 | Practical work - Pharmaceutical technologies and Biopharmacy
Corequisite
| B1 | Q2 | - | 32 | - | 2 |
| PHAC0342-2 | Special pharmacology (Part II)
Corequisite
| B1 | Q2 | 20 | - | - | 2 |
| TOXI0342-2 | Clinical Toxicology and adverse drug events monitoring (Part II) - [12h Seminar]
Corequisite
| B1 | Q2 | 25 | - | [+] | 4 |
| BIOC0341-1 | Clinical chemistry (2nd part) - [12h Seminar]
Corequisite
| B1 | Q2 | 23 | - | [+] | 4 |
| PHAR0004-1 | Pharamcotherapy and pharmaceutical cares - [10h Seminar] | B1 | Q2 | 30 | - | [+] | 4 |
| SANT0005-1 | Therapeutic approach - [20h Séminaire Interdisciplinaire] | B1 | Q2 | - | - | [+] | 2 |
| LEGI0340-2 | Legislation and pharmaceutical ethics | B1 | Q2 | 30 | - | - | 3 |
| PHAR2121-1 | Practical integrated work
Brigitte Evrard, Marianne Fillet, Pierre Francotte, Michel Frederich, Anna Lechanteur, Allison Ledoux, Géraldine Piel, Anne-Catherine Servais, Eric Ziemons
Corequisite
| B1 | Q2 | - | 32 | - | 2 |
| PHAR2226-1 | Innovative therapy medications | B1 | Q2 | 10 | - | - | 1 |
| APPR0160-2 | Professional development Seminar - [30h Learning based on problem-solv]
Laetitia Buret, Etienne Cavalier, Corinne Charlier, Alain Chaspierre, Raphaël Denooz, Brigitte Evrard, Marianne Fillet, Pierre Francotte, Michel Frederich, Anna Lechanteur, Frédéric Lecomte, Frédéric Lecomte, Anne-Laure Lenoir, Geneviève Philippe, Géraldine Piel, Anne-Catherine Servais, Eric Ziemons
Corequisite
| B2 | Q2 | - | - | [+] | 5 |
| APPR1003-1 | Interdisciplinarity and vaccination | B2 | Q2 | 1 | |||
| Interdisciplinarity - [12h Seminar] | 2 | 2 | [+] | ||||
| Vaccination - [8h Seminar] | - | - | [+] | ||||
Compulsory Training |
|||||||
| MTFE0351-3 | Officinal Internship and Thesis | B2 | Q2 | 24 | |||
| Record of learning and participation to clinical research project - [100h Personal research] | - | - | [+] | ||||
| Officinal internship and Thesis - [6mois internship]
Prerequisite
Corequisite
| - | - | [+] | ||||
| Notice : students must do a placement in a pharmacy of a legal duration of six months (26 weeks), and compile a learning record (dissertation) at the same time. This placement includes a compulsory introductory two-week internship, during the summer, after the bachelor's degree. For students who have acquired a minimum of 45 ECTS from block 1 of the master's degree, they can do their placement in a pharmacy during the summer holidays before starting block 2 of the master's degree (maximum 8 weeks). The remaining number of weeks (minimum 16 weeks) can be done within the framework of block 2 of the master's (2nd term). | |||||||
| PHAR0721-1 | Incorporation of pharmaceutical knowledge
Corinne Charlier, Raphaël Denooz, Brigitte Evrard, Marianne Fillet, Pierre Francotte, Michel Frederich, Julien Hanson, Patrick Herné, Frédéric Lecomte, Geneviève Philippe, Géraldine Piel, Bernard Pirotte, Anne-Catherine Servais, Vincent Seutin
Corequisite
| B2 | Q2 | - | 50 | - | 5 |
| Code | Details | Bloc | Organization | Theory | Practical | Others | Credits |
|---|---|---|---|---|---|---|---|
| PHAR2228-1 | Specific courses for the research focus in drug design and development - bioanalysis (Part I) | B1 | Q2 | 5 | |||
| Natural raw materials | - | 20 | - | ||||
| Analysis of biological drugs and drugs in biofluids | 10 | - | - | ||||
| Drug design | 10 | - | - | ||||
| Industrial pharmaceutical technology | 10 | - | - | ||||
| Sterilisation methods
Aurore Napp, Isabelle Roland, Gaëtan Van Haren
| 10 | - | - | ||||
| PHAR2230-1 | Specific courses for the research focus on drug design and development - bioanalysis | B2 | Q1 | 5 | |||
| Quality in the pharmaceutical industry and regulation | 10 | - | - | ||||
| Specific concepts in clinical biology | 10 | - | - | ||||
| Additional pharmacokinetics | 10 | - | - | ||||
| Critical analysis of clinical studies | 10 | - | - | ||||
| Radiopharmacy
Pierre Francotte, Mallory Salvé, Frédéric Schmitz
| 10 | - | - |
Focus optional courses
- B2
- 20Cr
| Code | Details | Bloc | Organization | Theory | Practical | Others | Credits | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||